Posts Tagged ‘low molecular weight heparin’

RSS

May 11th, 2015

Selections from Richard Lehman’s Literature Review: May 11th

This week’s topics include a comparison of catheter ablation for persistent AF, left atrial appendage exclusion with the Lariat device, the obesity paradox in type 2 diabetes, and more.


February 23rd, 2015

Selections from Richard Lehman’s Literature Review: February 23rd

This week’s topics include a comparison of fondaparinux and low-molecular-weight heparin in patients with non-STEMI and a study of multiple BP medications, achieved BP, and mortality in older nursing home residents.


November 3rd, 2014

Economic Study Finds VTE Prophylaxis with Low-Molecular-Weight Heparin Cost Effective

Critically ill patients in the hospital are at high risk for developing venous thromboembolism (VTE). The 2011 PROTECT trial compared the two most common drug strategies used to prevent VTE — unfractionated heparin (UFH) and dalteparin, a low-molecular-weight heparin (LMWH) —  and found no difference between the two groups in the primary endpoint of the trial, leg deep-vein thrombosis. But […]


June 10th, 2013

Selections from Richard Lehman’s Literature Review: June 10th

This week’s topics include controlling diabetes through surgery or medical management, the risk for diabetes among those taking statins, and aspirin vs. low-molecular-weight heparin for extended VTE prophlyaxis after total hip replacement.


August 8th, 2012

Selections from Richard Lehman’s Literature Review: August 8th

This week’s topics include heart failure and depression, endoscopic vs. open vein-graft harvest for CABG, linagliptin vs. glimepiride in those with type-2 diabetes, weight gain with smoking cessation, ACE inhibitors and pneumonia risk, and the effect of speech therapy after stroke.


December 28th, 2011

No Mortality Benefit of Low-Molecular-Weight Heparin in Acutely Ill Patients

Although venous thromboembolism (VTE) is a serious problem for acutely ill patients in the hospital, a new study published in the New England Journal of Medicine failed to find any improvement in mortality associated with thromboprophylaxis. Ajay Kakkar and the LIFENOX investigators randomized 8307 acutely ill patients to receive enoxaparin or placebo for 10 days. All patients wore elastic […]


July 23rd, 2010

FDA Approves Generic Enoxaparin

The FDA announced on Friday that it had approved the first generic enoxaparin sodium injection for multiple indications including prevention of deep vein thrombosis (DVT). The action represents the FDA’s first generic approval of a low molecular weight heparin. The original version of enoxaparin, Lovenox, was first approved in 1993. To gain approval as a generic, […]